Pulmicort HFA (budesonide aerosolized formulation) / AstraZeneca - LARVOL DELTA

AZN: full-year 2020 results (Cisionwire) - P3, N=60; TYREE (NCT04234464); Sponsor: Bond Avillion 2 Development LP; "Total Revenue declined by 1% in the year (stable at CER) to $5,375m...This included Ongoing Collaboration Revenue of $18m from Duaklir, Eklira and other medicines. Symbicort: Total Revenue, entirely comprising Product Sales, amounted to $2,721m in the year and represented an increase of 9% (10% at CER), a result of growth in the US. Q4 2020 Total Revenue declined by 5% to $680m...Pulmicort: Total Revenue, entirely comprising Product Sales, amounted to $996m in the year and represented a decline of 32%...Q4 2020 Total Revenue declined by 11% (14% at CER) to $368m....TYREE Phase III trial achieved its primary endpoint....PT027 demonstrated superiority over placebo for the primary endpoint of the maximum percentage fall from post-dose, pre-exercise baseline in forced expiratory volume in one second observed up to 60 minutes, post-exercise challenge....Timing - 2022 - PT027 - asthma: regulatory submission."

P3 data • Regulatory • Sales • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

AstraZeneca PLC - Third quarter and nine months results 2011 (AstraZeneca) - Symbicort sales in the US were $201 million in the third quarter a 15% increase over last year and US sales for past nine months were $604M an increase of 14%; Symbicort sales in other markets in the third quarter were $554M in Japan,Canada, Australia and emerging Europe 7% ahead of the third quarter last year; Pulmicort in the third quarter were down 15% to $52M and nine months sales were down by 8%; Due to the lack of efficacy in a P2b trial, the decision was made to discontinue the development programme for MEDI-528

Quarterly results • Sales update • Asthma

Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary Disease (CHEST 2011) - P3, N=308; NCT00421122; BUD/FORM improved COPD symptom total scores (p=0.03), reduced reliever use (p=0.012) and improved total SGRQ score -4.5 points (p=0.0182) vs BUD alone; Fixed combination treatment with BUD/FORM resulted in clinically meaningful improvements compared with BUD alone for lung function, quality-of-life, COPD symptoms and a reduction in reliever use, and it was well tolerated

P3 data • Asthma